(Q36977426)

17 August 2017

3 references

25 April 2019

17 September 2019

14 October 2020

Pegaptanib sodium for ocular vascular disease (English)

1 reference

17 August 2017

3 references

25 April 2019

17 September 2019

14 October 2020

1 reference

17 September 2019

1 reference

14 October 2020

Dhananjay Shukla

1

1 reference

17 August 2017

Perumalsamy Namperumalsamy

series ordinal

2

1 reference

17 August 2017

Mauro Goldbaum

series ordinal

3

1 reference

17 August 2017

Emmett T Cunningham

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Indian Journal of Ophthalmology

17 August 2017

4 references

17 August 2017

25 April 2019

17 September 2019

14 October 2020

55

1 reference

17 August 2017

6

1 reference

17 August 2017

427-430

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

17 August 2017

3 references

25 April 2019

17 September 2019

on focus list of Wikimedia project

14 October 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Ranibizumab for neovascular age-related macular degeneration

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Vascular endothelial growth factor: basic science and clinical progress

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Pegaptanib for neovascular age-related macular degeneration

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

VEGF164Is Proinflammatory in the Diabetic Retina

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635976

Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17951898

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4103/0301-4738.36476

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

17951898

1 reference